Figure 5
From: Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031
DCK and DCTPP1 simultaneous knockdown induced no synergistic effect in pancreatic and ovarian cancer cells to NUC-1031. (A) DCK and DCTPP1 protein expression analyzed by Western blot in MiaPaCa2 and A2780 cells transfected with a pX333 plasmid containing sgRNA sequences targeting DCK (sgDCK) and DCTPP1 (sgDCTPP1) or a non-targeting scrambled control sgRNA (sgScr). (B) Dose response curves for MiaPaCa2 and A2780 sgDCK-sgDCTPP1 cells and sgScr-sgScr cells (control), 4d after treatment with NUC-1031 or gemcitabine (n = 6, +/−SEM. MiaPaCa2 sgScr-sgScr vs MiaPaCa2 sgDCKe-sgDCTPP1a: p = 0.0022, A2780 sgScr vs A2780 sgDCK-sgDCTPP1: p = 0.0022; Mann-Whitney test).
